Changshan Center for Disease Control and Prevention
Quzhou, Zhejiang, 324200, China
NCT Number: NCT03168412
This phase IV clinical study was designed to evaluate the immunogenicity and safety of the recombinant Hepatitis E vaccine (Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults (over 18 years) with accelerated vaccination schedule. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-7-21 days schedule or a 0-1-6 month schedule.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Quzhou, Zhejiang, 324200, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Other names: Hecolin®
Time frame: up to 2 months
Measure anti-HEV antibody in serum samples at 51st day to evaluate the immunogenicity of the Hepatitis E vaccine.
Time frame: up to 7 months
Measure solicited local adverse reactions/events within 7 days after each vaccination; Measure solicited systematic adverse reactions/events within 7 days after each vaccination; Measure unsolicited adverse reactions/events within 30 days after vaccination; Measure serious adverse events occurred throughout the study(up to 7 months).
Time frame: up to 7 months
Measure anti-HEV antibody in serum samples at 21st day,28st day and month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Time frame: up to 7 months
Measure anti-HEV antibody in serum samples at month 1,2,7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Xiamen Innovax Biotech Co., Ltd
Industry
A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07729202
Digestive System Diseases, Hepatitis
Les Abymes, Guadeloupe
View Trial DetailsNCT02190253
Digestive System Diseases, Hepatitis
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06564116
Digestive System Diseases, Hepatitis
Sanming, Fujian, China
View Trial DetailsNCT03827395
Digestive System Diseases, Hepatitis
Atlanta, Georgia, United States
View Trial Details